Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IDE modifications reg

This article was originally published in The Gray Sheet

Executive Summary

Publication of a final version of the rule could be held up until after the Nov. 21 deadline stipulated by the FDA Modernization Act because the Office of Management and Budget has determined that the rule is "significant" and worthy of OMB's review, FDAers say. OMB has 90 days from June 17 to review the rule before it can be issued as a proposed rule in the Federal Register. The rule, which will spell out which modifications may be made to an investigational device exemption product or protocol without FDA notification, is one of eight rules and guidances that the agency's device center had planned for release by September ("The Gray Sheet" June 29, p. 7)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel